Group 5B: HER2+, HER2-low Breast Cancer; Antibody-Drug Conjugates; Clinical Trials; Treatment Resistance

Poster #TPS1122: An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).

Poster #TPS1123: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).


Jun 13 2024


2:00 pm - 3:30 pm

Zoom Webinar